Subtype
Pharyngeal Neoplasm
CI-CAN-00001414Explore in graph →
Non-malignant421 active trials1 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001414Explore in graph →
Clinical trials
1,344 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)(OPPIDOM) | terminated | N/A | 8 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | terminated | Phase 3 | 10 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | terminated | Early Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | terminated | Phase 1 | 4 | Hyunseok Kang, MDOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 2 | 13 | University of UtahOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02875613 | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | terminated | Phase 2 | 6 | Assuntina Sacco, M.D.OTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma(NPC) | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT03555721 | CytID Analysis of Oral Lesions | terminated | — | 18 | The University of Texas Health Science Center, HoustonOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 20 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | terminated | Phase 2 | 2 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | terminated | Early Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | terminated | N/A | 1 | Paul W. Read, MDOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03713021 | TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers | terminated | N/A | 27 | Washington University School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04015336 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02874651 | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy(ADVANCE) | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT00011492 | Patient Evaluation for Head and Neck Surgery Branch Studies | terminated | — | 62 | National Institute on Deafness and Other Communication Disorders (NIDCD)NIH | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01687413 | Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer(ADEPT) | terminated | Phase 3 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT03479463 | Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy | terminated | — | 8 | MiMedx Group, Inc.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00393224 | Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families | terminated | — | 952 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01257100 | Environmental and Genetic Determinants of NPC | terminated | — | 3,500 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck(AGMT_HNO_PN) | terminated | Phase 3 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01883908 | Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer(GCC1229) | terminated | N/A | 4 | University of Maryland, BaltimoreOTHER | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01230476 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma | terminated | Phase 2 | 3 | University of MalayaOTHER | 1 | Oct 7, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials